www.fdanews.com/articles/123475-mylan-8217-s-mirapex-antitrust-lawsuit-is-subject-of-boehringer-motion
Mylan’s Mirapex Antitrust Lawsuit Is Subject of Boehringer Motion
January 7, 2010
Responding to a Mylan Pharmaceuticals
antitrust lawsuit, Boehringer Ingelheim has filed a motion to dismiss the case in which Mylan contends the drugmaker took unlawful action to protect an
invalid patent on its Parkinson’s disease drug Mirapex. The motion to dismiss was filed in the U.S. District Court
for the Western District of Pennsylvania. Boehringer contends that its defeat in a previous Mirapex (pramipexole dihydrochloride) patent case is not enough
to prove it is guilty of an antitrust violation, according to court documents.
Generic Line
Generic Line